Hanson Wade’s Targeted Protein Degradation Conference
“Encapsulating the excitement of the field of protein degradation, the 2nd TPD Summit 2019 is the definitive comprehensive and industry-dedicated summit for the field of protein degradation – focused on optimizing target validation, improving medicinal chemistry & rational design, and ultimately accelerating the translation of selective, bioavailable and effective protein degraders into clinical trials.” Progenra […]
Cambridge Healthtech Institute’s Annual Discovery on Target Conference
CHI’s conference on PROTACs and Targeted Protein Degradation will bring together a diverse group of chemists and biologists to discuss the prospects as well as the challenges underlying strategies for targeted protein degradation. This will be preceded by a conference that discusses emerging ubiquitin and autophagy targets for therapeutic intervention. Progenra CEO Dr. Butt will […]
International BIO Convention in Philadelphia
More than 18,000 attendees from companies in 67 countries will meet to “celebrate the global importance of innovation in biotech.” Progenra looks forward to meeting with collaborators and future partners and learning about the latest technological innovations and ideas in drug discovery. This is the largest gathering of Biotech professionals in the world, and we are lucky enough to […]
Neurodegenerative Drug Discovery Europe Conference
Paris, France. ” Multiple clinical failures in the neurodegenerative field have sparked realization that there is a critical need for discussion and debate between neurodegenerative drug developers to drive clinical success. NDD Europe will overcome the translational challenges facing neurodegenerative drug developers by exploring the future biomarkers of neurodegeneration, improving preclinical modelling to increase clinical predictability […]
Progenra Inc. Receives Therapeutic Pipeline Award from The Michael J. Fox Foundation for Parkinson’s Research and Drug Development
Funding will support Progenra’s development of small molecules for treatment of Parkinson’s Disease Malvern, PA (Dec 8, 2018) – Progenra Inc. announces the receipt of a 2018 Therapeutic Pipeline Award from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The award supports Progenra’s program of small molecule drug discovery and development for Parkinson’s disease, […]
Drug Discovery Chemistry
San Diego, CA. First-generation cancer immunotherapy agents have been primarily biologicals — monoclonal antibodies that block protein-protein interactions between T cell checkpoint receptors and their ligands. Recently, discovery efforts have focused on the development of immune-modulatory small molecules addressing a wide array of new immune-modulatory targets that can be used in combination with the biologicals. […]
American Chemical Society National Meeting and Exposition
New Orleans, LA. Dr. Jian Wu, Associate Director at Progenra, presented a talk entitled ” Small molecules as frontline therapy for immune oncology: Experience from ubiquitin pathway targets ” at medicinal chemistry section. The ACS National Meeting brings together more than 10,000 professionals to present and discuss recent publications as well as technological advancements. The spring […]
Progenra discusses role of small molecules and USP7 in immune oncology on Cambridge Healthtech Institue podcast
Recently, Dr. Tauseef Butt, President and CEO, spoke with Joel Hornby of Cambridge Healthtech Institute. Dr. Butt spoke of the role that small molecules, specifically inhibitors of ubiquitin protease 7 (USP7), play in immune oncology. In addition, Dr. Butt discussed animal model data generated using Progenra’s USP7i compounds, as well as Progenra’s unique Drug Discovery […]
Progenra invited to host an Immune Oncology Session at BIO International Convention 2017
June 18-22, 2017. San Diego, CA. Progenra President Dr. Tauseef Butt is the organizer and a participant of a panel discussion entitled “Immune Oncology Drugs: Ready for First Line Therapy?” This panel, which is comprised of leaders of immune oncology from the pharmaceutical industry and academic medicine, will address whether the new immune oncology drugs […]
Progenra Receives Second Immune Oncology Patent
MALVERN, PA, May 10, 2017 –(BUSINESS WIRE) — Progenra, Inc. announced that it has received the Official Notice of Allowance (dated March 30, 2017) of its patent application entitled “Methods of treating cancer through the inhibition of USP7 and immune system modulation.” The patent, based on work described in a recent publication, is related to a […]